Table 1 Cardiovascular and kidney outcomes reported in selected meta-analyses of CVOTs of GLP-1RAs and SGLT2is
Outcome | GLP-1RAs | SGLT2is | ||
|---|---|---|---|---|
| Â | HR (95% CI) | p-value | HR (95% CI) | p-value |
Meta-analysis by Zelniker et al. [3] of 5 GLP-1RA trials and 3 SGLT2i trials | ||||
 MACE | 0.88 (0.84–0.94) |  < 0.001 | 0.89 (0.83–0.96) | 0.001 |
  MACE in established ASCVD | 0.87 (0.82–0.92) | NA | 0.86 (0.80–0.93) | NA |
  MACE without established ASCVD | 1.03 (0.87–1.23) | NA | 1.00 (0.87–1.16) | NA |
 HHF | 0.93 (0.83–1.04) | 0.20 | 0.69 (0.61–0.79) |  < 0.001 |
 Risk of stroke | 0.86 (0.77–0.97) | 0.012 | 0.97 (0.86–1.10) | 0.64 |
 Kidney outcomes | 0.82 (0.75–0.89) |  < 0.001 | 0.62 (0.58–0.67) |  < 0.001 |
 Kidney outcomes without macroalbuminuria | 0.92 (0.80–1.06) | 0.24 | 0.55 (0.48–0.64) |  < 0.001 |
Outcome | HR (95% CI) | p-value |
|---|---|---|
Meta-analysis by Sattar et al. [29] of 8 GLP-1RA trials | Â | Â |
 MACE | 0.86 (0.80–0.93) |  < 0.0001 |
  MACE in established ASCVD | 0.85 (0.78–0.92) | NA |
  MACE without established ASCVD | 0.94 (0.83–1.06) | NA |
 HHF | 0.89 (0.82–0.98) | 0.013 |
 Risk of stroke | 0.83 (0.76–0.92) | 0.0002 |
 Kidney outcomes | 0.79 (0.73–0.87) |  < 0.0001 |
 Kidney outcomes without macroalbuminuria | 0.86 (0.72–1.02) | 0.089 |
Meta-analysis by Lee et al. [85] of 9 GLP-1RA trials | ||
 MACE | 0.87 (0.81–0.94) | 0.00065 |
Meta-analysis by McGuire et al. [86] of 6 SGLT2i trials | ||
 MACE | 0.90 (0.85–0.95) | NA |
 MACE in established ASCVD | 0.89 (0.84–0.95) | NA |
 MACE without established ASCVD | 0.94 (0.83–1.07) | NA |
HHF | 0.68 (0.61–0.76) | NA |
Kidney outcomes | 0.62 (0.56–0.70) | NA |